Safety Management of Incretin-Based Obesity Therapy: Expert Consensus on the Use of Semaglutide and Tirzepatide

On December 3, 2025, a meeting of the expert working group was held in Moscow. The discussion focused on the safety and personalized use of tirzepatide (Tirzetta®) and semaglutide (Velgia® eco) in patients with overweight and obesity. Following the meeting, a consensus position was developed on the optimal use of incretin receptor agonists in real-world clinical practice.

1. Troshina EA, Antsiferov M.B., Ametov AS, Galstyan GR, Markova TN, Romantsova TI, Mazurina NV, Koteshkova OM. A personalized, evidence-based approach to obesity therapy using clinical algorithms: semaglutide or tirzepatide. Problems of Endocrinology. 2025;71(5):19-30. (In Russ.) doi: https://doi.org/10.14341/probl13677

2. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387:205-16. doi: https://doi.org/10.1056/NEJMoa2206038

3. Aronne LJ, Sattar N, Horn DB, et al.; SURMOUNT-4 Investigators. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024;331(1):38-48. doi: https://doi.org/10.1001/jama.2023.24945

4. Colhoun HM, Lingvay I, Brown PM, et al. Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial. Nat Med. 2024;30(7):2058-2066. doi: https://doi.org/10.1038/s41591-024-03015-5

5. Yao H, Zhang A, Li D, et al. Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis. BMJ. 2024;384:e076410. doi: https://doi.org/10.1136/bmj-2023-076410

6. Aronne LJ, Horn DB, le Roux CW, et al.; SURMOUNT-5 Trial Investigators. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. N Engl J Med. 2025. doi: https://doi.org/10.1056/NEJMoa2416394

7. Du Y, Zhang M, Wang Z, et al. A real-world disproportionality analysis of semaglutide: Post-marketing pharmacovigilance data. J Diabetes Investig. 2024. doi: https://doi.org/10.1111/jdi.14229

8. Wharton S, Calanna S, Davies M, et al. Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss. Diabetes Obes Metab. 2022;24(1):94-105

9. Gorgojo-Martínez JJ, Mezquita-Raya P, Carretero-Gómez J, et al. Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated with Glp-1 Receptor Agonists: A Multidisciplinary Expert Consensus. J Clin Med. 2022;12(1):145. doi: https://doi.org/10.3390/jcm12010145

10. Salukhov VV, Galstyan GR, Khalimov IS, Bakulin IG, Cherkashin DV, Shadrichev FE, Sukhotskaia NA. Practical application of semaglutide: From evidence-based research to expert decisions. Meditsinskiy sovet = Medical Council. 2025;(6):14-29 (In Russ.) doi: https://doi.org/10.21518/ms2025-185

11. Hampel H, Abraham NS, El-Serag HB. Meta-analysis: obesity and the risk for gastroesophageal reflux disease and its complications. Ann Intern Med. 2005;143(3):199-211

12. Hsu WH, Geng JH, Wu PY, et al.. Metabolic syndrome is associated with gastroesophageal reflux disease in a large Taiwanese population study. Int J Med Sci. 2025 Feb 28;22(7):1555-1561

13. Singh M, Lee J, Gupta N, et al. Weight loss can lead to resolution of gastroesophageal reflux disease symptoms: a prospective intervention trial. Obesity (Silver Spring). 2013;21(2):284-90

14. Parra-Landazury NM, Cordova-Gallardo J, Méndez-Sánchez N. Obesity and Gallstones. Visc Med. 2021;37(5):394-402

15. Gebhard RL, Prigge WF, Ansel HJ, et al. The role of gallbladder emptying in gallstone formation during diet-induced rapid weight loss. Hepatology. 1996;24(3):544-8

16. Troshina EA, Suplotova LA, Dzgoeva FKh, et al. The opportunities to improve therapy adherence in patients with overweight and obesity in real clinical practice. Problems of Endocrinology. 2026;72(1):89-98. (In Russ.) doi: https://doi.org/10.14341/probl13737

17. Stokes C, et al. Ursodeoxycholic Acid and Diets Higher in Fat Prevent Gallbladder Stones During Weight Loss: A Meta-analysis of Randomized Controlled Trials. Clin Gastroenterol Hepatol. 2014;12:1090–1100

18. Mechanick JI, et al. Clinical practice guidelines for the perioperative nutrition, metabolic, and nonsurgical support of patients undergoing bariatric procedures – 2019 update. Surg Obes Relat Dis. 2020;16(2):175–247

19. Bischoff SC, Barazzoni R, Busetto L, et al. European guideline on obesity care in patients with gastrointestinal and liver diseases - Joint ESPEN/UEG guideline. United European Gastroenterol J. 2022 Aug. doi: https://doi.org/10.1002/ueg2.12280

20. Ministerstvo zdravoohraneniya Rossijskoj federacii. Klinicheskie rekomendacii «Nealkogol’naya zhirovaya bolezn’ pecheni u vzroslyh», Rossiya, 2024 (In Russ.)

21. Ministerstvo zdravoohraneniya Rossijskoj federacii. Klinicheskie rekomendacii «Zhelchnokamennaya bolezn’», Rossiya, 2024. (In Russ.)

22. Jiang K, Chen B, Lou D, et al. Systematic review and meta-analysis: association between obesity/overweight and surgical complications in IBD. Int J Colorectal Dis. 2022;37(7):1485-1496

23. Stamboltsyan V.Sh., Bakulin I.G., Aslanov B.I., Kirillova A.A. Inflammatory bowel diseases: epidemiology and risk factors (review). Koloproktologia. 2024;23(4):148-158 (In Russ.) doi: https://doi.org/10.33878/2073-7556-2024-23-4-148-158

24. Gorelik Y, Ghersin I, Lujan R, et al. GLP-1 Analog Use is Associated With Improved Disease Course in Inflammatory Bowel Disease: A Report from the Epi-IIRN. J Crohns Colitis. 2025;19(4): jjae160. doi: https://doi.org/10.1093/ecco-jcc/jjae160

25. Gofron KK, Wasilewski A, Małgorzewicz S. Effects of GLP-1 Analogues and Agonists on the Gut Microbiota: A Systematic Review. Nutrients. 2025;17(8):1303. doi: https://doi.org/10.3390/nu17081303

26. Sherf-Dagan S, et al. Micronutrient deficiencies in patients after bariatric surgery: a systematic review and meta-analysis. Obes Rev. 2023;24(1):e13523